Abstract Hospital readmission rate is an integral quality of care measurement for hospitalized patients which is unknown for intestinal Behçet's disease cases. The purpose of this study was to investigate the risk factors and outcomes for patients readmitted early with intestinal Behçet's disease. We retrospectively reviewed patients with intestinal Behçet's disease who were readmitted to our hospital between 2005 and 2016. We then analyzed the risk factors and outcomes for early readmission within 3 months. Of the 204 patients who were readmitted, 103 patients (50.5%) were readmitted within 3 months and 101 (49.5%) were never readmitted or readmitted after 3 months. After multivariate analysis, hospital stay at the first admission (adjusted odds ratio [OR], 0.945; 95% confidence interval [CI], 0.908-0.982; P = 0.004), high disease activity index for intestinal Behçet's disease score (adjusted OR, 1.111; 95% CI, 1.060-1.165; P < 0.001), corticosteroid use (adjusted OR, 3.179; 95% CI, 1.135-8.910; P = 0.028), and opioid use (adjusted OR, 7.979; 95% CI,; P = 0.041) were independent factors for early readmission. We identified four independent prognostic factors for early readmission within 3 months, which might help guide appropriate management strategies for hospitalized patients with intestinal Behçet's disease.
Introduction
Behçet's disease (BD) is a chronic multisystemic immunemediated disorder with an unknown etiology characterized by recurrent oral and/or genital ulcerations, arthritis, skin manifestations, and ocular, vascular, neurological, and intestinal involvement [1, 2] . Intestinal BD is diagnosed when patients with BD have gastrointestinal (GI) symptoms, typical single ulcerative lesions that are circular/oval, and deep or multiple ulcers in the ileocecal area documented by objective measures Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10067-017-3904-2) contains supplementary material, which is available to authorized users. [3, 4] . GI manifestations usually occur 4.5-6 years after the onset of oral ulcers [5] , and the most frequently involved sites are the terminal ileum and the cecum with esophageal involvement being very rare [6] . Involvement of the entire GI tract is uncommon but leads to severe morbidity and mortality [7] . Intestinal BD symptoms range from mild abdominal discomfort to severe abdominal pain, and patients can have further complications such as GI bleeding, fistula, or perforation [1, 4] . Abdominal pain associated either with or without diarrhea, bleeding, nausea, vomiting, bowel habit change, or weight loss is most commonly observed [1] . In particular, hemorrhage or bowel perforation can be life-threatening and could lead to an increased chance for morbidity and mortality [1] .
Hospital readmission rate is becoming an integral measure of the quality of care for hospitalized patients with acute and chronic diseases [8] . Lowering the readmission rate is crucial not only for hospital quality and performance evaluation purposes, but also for patients for avoiding direct and indirect burdens and costs of hospitalization [9] . Therefore, several studies have assessed the risk factors and incidence of early readmission in patients with inflammatory bowel diseases (IBDs), including both Crohn's disease (CD) and ulcerative colitis (UC) [9] [10] [11] . However, although there are patients with intestinal BD that causes significant GI symptoms similar to those with IBD, there is no study on the risk factors and readmission outcomes for these patients. Therefore, the aim of this study was to evaluate the outcomes and risk factors for early readmission (within 3 months) in patients with intestinal BD.
Method Patients
This is a retrospective study of patients hospitalized due to intestinal BD between January 2005 and December 2016 at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. The diagnosis of intestinal BD was made as previously described based on colonoscopic features and clinical manifestations using a modified Delphi process [3] . The patients were classified as Bdefinite,^Bprobable,^or Bsuspected^ [1, 3] . Of 253 admitted patients with intestinal BD, 49 patients were excluded from this study for the following reasons: (i) patients were later diagnosed as having other diseases such as CD, UC, intestinal tuberculosis, or nonspecific colitis during the follow-up period (n = 15); (ii) patients were admitted for other reasons not associated intestinal BD due to the occurrence of ovarian cancer, renal cell carcinoma, or stomach cancer or for regular infliximab injection only (n = 30); and (iii) pediatric patients were under 18 years (n = 4) (Fig. 1) . The remaining 204 patients were enrolled in our study and divided into two groups: 103 patients who were readmitted within 3 months were designated as the Bearly-readmission group,^a nd the other 101 patients were designated as the Bno-or latereadmission group,^including those who were readmitted later than 3 months and those who were not readmitted and were followed up only at outpatients clinics (Fig. 1) . This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Institutional Review Board of Severance Hospital.
Baseline characteristics
The baseline characteristics of the patients were obtained from the electronic medical data during hospitalizations and clinic visits, including patient demographics, length of hospital stay, comorbid disease, reason for admission, process of admission, bowel resection surgical records, disease activity index for intestinal Behçet's disease (DAIBD) score, endoscopic findings, laboratory findings such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, and type of medical treatment.
The medications prescribed included 5-aminosalicylic acid (5-ASA/sulfasalazine), immune modulators (azathioprine and 6-mercaptopurine ), corticosteroids, and antitumor necrosis factor agents [1] . Based on the previous studies [1, 12] , positive treatment outcomes are expected if the patients receive a full dose (azathioprine, 2-2.5 mg/kg per day, or 6-MP, 1-1.5 mg/kg per day) of immunomodulators during the course of the disease. For patients treated with either intravenous or oral corticosteroid therapy, a positive outcome is expected if they are given an equivalent dose of prednisolone of 0.5-1 mg/g per day for at least 2 months. Moreover, infliximab leads to a positive outcome if the patients are given a dose of 5 mg/kg for at least three infusions at 0, 2, and 6 weeks [1] . In addition, we evaluated the medications used for symptom management including antibiotics, opioids, antianxiety drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). We also investigated the presence of bowel surgery including ileocecectomy, right hemicolectomy, and segmental small-bowel resection, and only primary intestinal repair without resection.
Definitions of variables
We divided the patients into two groups-those who were readmitted within 3 months, designated as the earlyreadmission group, and those who were not readmitted within 3 months, designated as the no-or late-readmission group, which included patients who were readmitted over 3 months after initial discharge from the hospital or were followed up only at outpatient clinics without readmission. Additional subgroup analysis was performed between the early-readmission group and those admitted after 3 months, designated as the Blate-readmission group^(n = 36), in order to investigate the effects of the duration from discharge to readmission.
To evaluate disease activity index (DAI) of intestinal BD, we used DAIBD using eight variables. Higher scores reflect more severe disease activity [13] .
Statistical analysis
Variables are expressed as median (interquartile range, IQR) or number (%). The baseline characteristics were compared using the independent Student's t test (or Mann-Whitney test) for continuous variables and the χ 2 test (or Fisher's exact test) for categorical variables, as appropriate. Independent predictors for the readmission group were analyzed using logistic regression analysis. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. The overall survival rates were analyzed using the Kaplan-Meier method and compared using the log-rank test. Data analysis was performed using SPSS software (version 20.0; SPSS Inc., Armonk, NY, USA). A P value of < 0.05 was considered statistically significant.
Results
Comparisons of baseline characteristics between the early-readmission and noor late-readmission groups [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , P = 0.582) were not significantly different between the earlyreadmission group and the no-or late-readmission group. The most common reason for readmission within 3 months was abdominal pain, and there was a significant difference between the two groups (87.3 vs. 67.3%, P = 0.001). In addition, the number of patients with symptoms of diarrhea (55.9 vs. 31.7%, P = 0.001) and fever (46.1 vs. 28.7%, P = 0.011) was significantly higher in the early-readmission group compared to the noor late-readmission group. The early-readmission group had a statistically significant increase in the number of patients receiving bowel resection surgery (68.9 vs. 30.7%, P < 0.001) and has higher DAIBD score .0], P = 0.004) than those in the no-or late-readmission group. The early-readmission group also tended to have different ulcer localization (multiple-site ulcer [15.5 vs. 4 .0%] and anastomotic-site ulcer [30.1 vs. 11.9%], P < 0.001). In addition, the medication types administered were significantly different between the two groups: 5-ASA (95.1 vs. 85.0%, P = 0.015), steroids (75.7 vs. 60.0%, P = 0.016), antibiotics (60.2 vs. 38.6%, P = 0.002), and opioids (15.5 vs. 4.0%, P = 0.005) ( Table 1) .
Risk factors for readmission within 3 months: comparison of the early-readmission group with the noor late-readmission group
After performing the univariate analysis, factors including the presence of abdominal pain (P = 0.001); diarrhea (P = 0.001); fever at the first admission (P = 0.013); bowel resection surgery (P < 0.001); higher DAIBD score (P < 0.001); volcano-type ulcer (P = 0.028); higher ESR (P = 0.004); higher CRP level (P = 0.043); use of 5-ASA (P = 0.021), corticosteroids (P = 0.017), antibiotics (P = 0.002), or opioids (P = 0.010); and ulcer location (P < 0.001) were significantly associated with early Table 2) .
Comparisons of baseline characteristics between patients with early readmission and late readmission
Eventually, 139 patients were readmitted in our study population, after excluding those who were not readmitted and were followed up only at outpatients clinics. We compared baseline characteristics between the early-readmission group and the late-readmission group. The early-readmission group showed a significantly higher the number of patients with abdominal pain (87.4 vs. 58.3%, P < 0.001) when admitted, higher rate of bowel resection surgery (68.9 vs. 33.3%, P < 0.001), higher Table 1 ).
Risk factors of readmission between early readmission and late readmission
When analyzed only for readmitted patients (n = 139), univariate analysis revealed the presence of abdominal pain (P < 0.001) and bleeding (P = 0.030), performance of bowel resection surgery (P < 0.001), high DAIBD score (P < 0.001), high ESR (P = 0.009), high CRP level (P = 0.029), and use of 5-ASA (P = 0.004) or antibiotics (P = 0.029) were significantly associated with early readmission (Supplementary Table 2 ). After performing multivariate analysis, factors including older age (adjusted OR, 1.047; 95% CI, 1.005-1.091; P = 0.029) and higher DAIBD score (adjusted OR, 1.101; 95% CI, 1.033-1.174; P = 0.003) were found to be statistically significant independent factors for readmission within 3 months after the first admission (Supplementary Table 2 ).
Survival rate and follow-up periods
During the follow-up period, the overall survival (mortality) rates did not show statistically significant differences between early-readmission group and the no-or late-readmission group (8.7% [follow-up periods; median 4.9 year, IQR 1.6-8.2 years] vs. 5.0% [follow-up periods; median 4.4 year, IQR 1.6-8.0 years]) (P = 0.303) (Fig. 2) .
Discussion
There have been several studies that evaluated clinical outcomes and prognosis with various clinical presentations of intestinal BD [1] . Jung et al. studied the clinical course of intestinal BD during the first 5 years and found five different clinical courses: (i) persistent remission or mild clinical activity (56.2%), (ii) experienced remission or mild clinical activity after the initial activity peak (15.4%), (iii) an increase in severity (2.3%), (iv) chronic continuous symptoms (6.9%), and (v) chronic intermittent symptoms (19.2%) [14] . Furthermore, other studies reported that the 5-year cumulative reoperation rate was 31.2% [15] . Therefore, the severity of clinical course and high risk of disease recurrence could explain the frequent admission rates of intestinal BD. In our study, we evaluated the outcomes and risk factors with special reference to early readmission (within 3 months) in patients with intestinal BD. As a result, the prognostic factors for early readmission in patients with intestinal BD were found to be shorter hospital stay at the first admission, higher DAIBD score, and the use of corticosteroids or opioids. One possible explanation for shorter hospital stay being a risk factor for early readmission is that patients with intestinal BD respond to medical treatments more slowly than those with CD or UC. Therefore, it might take more time to completely relieve symptoms and signs of intestinal BD during hospitalization. The most common cause of admission in our study was abdominal pain (77.3%), and the complete relief of abdominal pain during admission is needed before discharge. If an incomplete relief of symptoms of hospitalized patients with intestinal BD happens, it might lead to early readmission.
The DAIBD model was constructed using the mean physician's global assessment (PGA) score as the dependent variable and graded items as the explanatory variables [13] . The items of weighting and DAIBD derivation include general well-being, fever, extra-intestinal manifestation, abdominal pain, abdominal tenderness, palpable mass, intestinal complication, and the number of liquid stools, which relate to disease activity [13] . In our study, higher DAIBD scores were a significant risk factor of readmission within 3 months and the DAIBD score reliably predicted the patient's disease activity. Therefore, we speculate that a higher disease activity leads to a higher corticosteroid use (e.g., prednisolone), which is usually used to treat 5-ASA-or immunomodulator-refractory patients, Fig. 2 Cumulative survival rates between the early-readmission group and the no-or late-readmission group those with severe systemic symptoms, or those with moderate to severe disease activity of intestinal BD [1] . Patients with higher DAIBD at admission should be carefully followed up during and after discharge.
Similar to our intestinal BD study, several studies reported the risk factors for readmission and cost effectiveness for IBD patients including CD and UC [8, 16, 17] . Allegretti et al. published about the risk factors for rehospitalization within 90 days for patients with IBD, which were depression, chronic pain, and steroid use [16] . Our analysis regarding narcotic usage showed that patients with intestinal BD who tended to suffer from severe clinical symptoms were more likely to be prescribed narcotics and these patients were more inclined to be rehospitalized. Regarding the use of corticosteroids in intestinal BD, there have been no prospective studies demonstrating the clinical efficacy of corticosteroids; however, many physicians have used this drug empirically for moderate to severe and refractory intestinal BD [18] . Park et al. reported that clinical remission and response rates to corticosteroid therapy in intestinal BD are 46 and 43%, respectively. However, 35.2% of patients who had clinical remission after 1 year eventually had steroid dependency [7] . Because of their relatively high dependence, it might be related that patients with steroids are likely to be readmitted more quickly. Our results suggest that steroid therapy only has a relieving effect of acute symptoms and further therapy replacing steroids should be initiated such as immunomodulators or anti-TNF agents to prevent disease flare-up and subsequent readmission.
Our study is the first study on the outcomes and risk factors for readmission in patients with intestinal BD. Previously, numerous studies investigating patients with CD and UC have been published, but there was a lack of data on patients with intestinal BD. In addition, we analyzed the use of various drug types such as opioids, antianxiety drugs, and NSAIDs and showed that patients with intestinal BD need to be treated similarly to those with CD and UC in order to alleviate clinical symptoms. Moreover, when we analyzed two different groups of patients readmitted within 3 months and later than 3 months, our multivariate analysis showed that higher DAIBD score was still an independent factor for readmission. This demonstrates that severe inflammatory conditions and clinical symptoms could lead to early readmission.
However, several limitations are present in our study. First, our study design was a retrospective study with potential confounding bias in one tertiary medical center. However, our hospital is the largest center for intestinal BD patients in the world. Second, we were not able to analyze the use of anti-TNF agents, because the number of anti-TNF users to analyze was too small to be analyzed. Third, we only analyzed two patient groups: those who were readmitted within 3 months and those who were not. This might have introduced selection bias to our analysis. Finally, we did not include the hospital index or costs. Therefore, further studies will be needed to improve the quality of care and decrease costs.
Conclusion
In summary, this study showed that shorter hospital stay at the first admission, higher DAIBD score, and steroid or opioid use were the independent prognostic factors for readmission within 3 months in intestinal BD patients. Therefore, we need to carefully control clinical symptoms and disease activity through the proper use of medications and/or surgery.
